Natco Pharma Ltd
NSE:NATCOPHARM
Natco Pharma Ltd
NSE:NATCOPHARM
Price:
1 015.2 INR
4.62%
Market Closed
Updated:
Jun 5, 2024
Natco Pharma Ltd
Pre-Tax Income
|
Natco Pharma Ltd
Pre-Tax Income Peer Comparison
Comparables:
DRREDDY
CIPLA
SUNPHARMA
ZYDUSLIFE
T
TORNTPHARM
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Natco Pharma Ltd
NSE:NATCOPHARM
|
Pre-Tax Income
₹15.2B
|
CAGR 3-Years
34%
|
CAGR 5-Years
8%
|
CAGR 10-Years
29%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Pre-Tax Income
₹72B
|
CAGR 3-Years
36%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Pre-Tax Income
₹57B
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
12%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Pre-Tax Income
₹105.1B
|
CAGR 3-Years
62%
|
CAGR 5-Years
19%
|
CAGR 10-Years
10%
|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Pre-Tax Income
₹48.1B
|
CAGR 3-Years
26%
|
CAGR 5-Years
15%
|
CAGR 10-Years
18%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Pre-Tax Income
₹21.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
21%
|
CAGR 10-Years
12%
|
See Also
What is Natco Pharma Ltd's Pre-Tax Income?
Pre-Tax Income
15.2B
INR
15.2B
INR
Based on the financial report for Dec 31, 2023, Natco Pharma Ltd's Pre-Tax Income amounts to 15.2B INR.
What is Natco Pharma Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
29%
29%
Over the last year, the Pre-Tax Income growth was 212%. The average annual Pre-Tax Income growth rates for Natco Pharma Ltd have been 34% over the past three years , 8% over the past five years , and 29% over the past ten years .
You don't have any saved screeners yet
